As per recommendations from the first International consensus meeting in 2019, response to AIHA treatment is defined as an increase in Hb by more than 2 g/dL or normalization of Hb without the biochemical resolution of hemolysis, along with no transfusions in the last seven days of treatment, while a complete response is characterized by Hb normalization, no evidence of hemolysis (normal bilirubin, LDH, haptoglobin, and reticulocyte levels), and no transfusions [8]. The gene discussed is HP; the disease is autoimmune hemolytic anemia.